Recently unlocked door: a fresh permission, approval, or qualification is already producing first real business
The model's full reasoning — Q1 2018 call → NOWe need answer YES or NO only. Need analyze transcript. Question: does management describe that company recently obtained a permission/approval/qualification/certification/listing/access right it did not previously hold — granted by outside authority, customer, partner, institution — newly allows company to sell/serve/operate where previously could not — AND that real first business through that newly opened door has ALREADY BEGUN, with most of what access permits still ahead? Need identify from transcript. There are several regulatory approvals mentioned. But need one coherent development with all three. Let's parse. Management mentions FDA approval for 23andMe direct-to-consumer cancer risk test. But that's for customer's product, not Illumina's own access? It may allow Illumina to sell microarray consumables to 23andMe? But management says "In March, 23andMe was granted the first FDA authorization for a direct to consumer genetic test for cancer risk. This highlights agency support..." This is an approval granted to 23andMe, not Illumina. It could be access for Illumina indirectly? But does management describe first business through that new access already begun? No, it's just regulatory environment progress. Not likely. CMS National Coverage Determination on NGS testing. Management says "In oncology, it's clear that even ahead of the recent CMS National Coverage Determination on NGS testing our customers are seeing mounting awareness..." "We are very pleased to see these meaningful developments that will accelerate clinical adoption of NGS..." But is this a recently obtained permission for Illumina? CMS coverage determination applies to NGS tests, likely for Medicare patients. It allows labs/customers to get reimbursement. But did Illumina obtain access right? It's an outside authority decision that newly allows? Management says "even ahead of recent CMS NCD..." "recent coverage decisions demonstrate regulatory and reimbursement environment progressing." But not necessarily Illumina's own permission to sell. Also first business through it? They mention customers benefiting, no specific Illumina revenue. Not likely. Rugged: "Also in first quarter, we launched the [MiSeq] study to demonstrate clinical utility of whole genome sequencing for acutely ill newborns... we are seeing growing adoption...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| RDCM | RADCOM Ltd. | Q4 2023 | 2024-01-31 | A |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| NVAX | Novavax, Inc. | Q3 2023 | 2023-11-09 | F |
| RVLV | Revolve Group, Inc. | Q3 2023 | 2023-11-01 | C |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| BMY | Bristol-Myers Squibb Company | Q4 2016 | 2017-01-26 | F |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
NVAX · Q3 2023 → YESThe question is: Does management describe that the company RECENTLY OBTAINED A PERMISSION, APPROVAL, QUALIFICATION, CERTIFICATION, LISTING, OR ACCESS RIGHT it did not previously hold — something grant...NO The transcript describes shipments of the updated COVID vaccine that began three weeks ago in the US after competitor launches, along with EU approval in October. However, these details do not meet the criteria for a YES answer because the transcript does not explicitly frame this as a newly obtained permission or access right that the company did not previously hold. Instead, it presents the launch as an update to their existing COVID-19 vaccine platform, with references to prior versions and the ability to update for seasonal strains.
MAT · Q3 2016 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent new partnership with Toys "R" Us for American Girl, granting exclusive store-within-store access that previously excluded the company. Initial shipping began in the first full quarter, with the distribution build still in early stages and most of the market potential ahead.
MAS · Q3 2018 → YESThe question is about whether management describes that the company recently obtained a permission, approval, etc., that it didn't previously hold, and that real first business through that newly open...YES The transcript shows management describing a recent program access at Menards that enables sales of stock cabinetry, with initial performance already underway and ramping toward an $80 million annual run rate in Q4—indicating the door is newly open and most of the potential volume remains ahead.